NeuroSense Therapeutics Ltd. (NRSN) Fair Value 2026

NRSN · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.6 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (33/100)

Quick Summary — As of 2026-08-28, NeuroSense Therapeutics Ltd. (NRSN) trades at $0.42. QOC: 4.6/10. Value Trap Risk: 33/100 (LOW). 0/13 models active.

Key Facts

Ticker
NRSN
Price
$0.42
Quality Score
4.6/10
Value Trap Risk
33/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.6/10 signals weak fundamentals

What Fair Value Does Each Model Give NRSN?

0 Intrinsic Value Models vs. Current Price ($0.42)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is NeuroSense Therapeutics Ltd. (NRSN) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, NeuroSense Therapeutics Ltd. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About NRSN?

0 of 13 models are currently active for NRSN. See which stocks rank higher →

How Does NRSN Rank in Biotechnology?

Among 625 Biotechnology stocks, NRSN ranks #434 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, NeuroSense Therapeutics Ltd. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating NRSN should weigh these sector-specific dynamics alongside our model-derived fair values.

Is NRSN a Value Trap?

CirclFi's Value Trap algorithm assigns NRSN a score of 33/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for NeuroSense Therapeutics Ltd.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, NeuroSense Therapeutics Ltd.'s fundamental quality profile registers 4.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NRSN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy NeuroSense Therapeutics Ltd. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

BCTXBriaCell Therapeutics Corp.QOC 4.6ATXIAvenue Therapeutics, Inc.QOC 4.6PTIXProtagenic Therapeutics, Inc.QOC 4.6PMNProMIS Neurosciences, Inc.QOC 4.5SIONSionna Therapeutics, Inc.QOC 4.6TILInstil Bio, Inc.QOC 4.5EIKNEikon Therapeutics, Inc.QOC 3.3XFORX4 Pharmaceuticals, Inc.QOC 6.3XBITXBiotech Inc.QOC 5.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: BCTX · ATXI · PTIX · PMN · SION · TIL · EIKN · XFOR · XBIT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to NRSN?

7 companies across all industries closest to NRSN’s Quality of Company score of 4.6/10.

HYFMHydrofarm Holdings Group, Inc.QOC 4.6SRFMSurf Air Mobility Inc.QOC 4.6GDVThe Gabelli Dividend & Income TrustQOC 4.6BTCTBTC Digital Ltd.QOC 4.6ORIBORIBQOC 4.6HYSRSunHydrogen, Inc.QOC 4.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: HYFM · SRFM · GDV · BTCT · ORIB · HYSR · NVDA

Where Does NRSN Sit in CirclFi's Biotechnology Rankings?

NRSN is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About NeuroSense Therapeutics Ltd.’s Valuation?

What is NeuroSense Therapeutics Ltd.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for NeuroSense Therapeutics Ltd. (NRSN). The Quality of Company score is 4.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NRSN overvalued or undervalued right now?

At $0.42, 0 of 0 active models suggest NRSN may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits NeuroSense Therapeutics Ltd.'s business model in Biotechnology.

What does a Quality of Company score of 4.6 mean for NRSN?

NeuroSense Therapeutics Ltd.'s QOC of 4.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NRSN?

CirclFi analyzes NRSN with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is NRSN a value trap in 2026?

NeuroSense Therapeutics Ltd.'s Value Trap score is 33/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns NeuroSense Therapeutics Ltd. (NRSN) a Quality of Company score of 4.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/NRSN/ · Methodology
Primary sources for this NRSN valuation
  • Financial statements: NeuroSense Therapeutics Ltd. 10-K and 10-Q filings on SEC EDGAR (CIK 0001875091) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NRSN as of ; valuations recomputed .